Get the Stockscreener App
1.11
10.48%
-0.13
After Hours:
1.12
0.01
+0.90%
Allarity Therapeutics Inc stock is traded at $1.11, with a volume of 373.54K.
It is down -10.48% in the last 24 hours and down -26.00% over the past month.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
See More
Previous Close:
$1.24
Open:
$1.2
24h Volume:
373.54K
Relative Volume:
0.44
Market Cap:
$5.50M
Revenue:
-
Net Income/Loss:
$-11.90M
P/E Ratio:
-0.00463
EPS:
-239.88
Net Cash Flow:
$-12.75M
1W Performance:
-6.72%
1M Performance:
-26.00%
6M Performance:
+92.78%
1Y Performance:
-88.92%
1-Day Range:
$1.10
$1.26
1-Week Range:
$1.10
$1.29
52-Week Range:
$0.1131
$22.20
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Name
Allarity Therapeutics Inc
Sector
Industry
Phone
401-426-4664
Address
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.11 | 5.50M | 0 | -11.90M | -12.75M | -239.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Allarity Therapeutics Inc Stock (ALLR) Latest News
Allarity Therapeutics stock hits 52-week low at $1.14 - Investing.com
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, I - GuruFocus.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus.com
Allarity Therapeutics stock hits 52-week low at $1.25 By Investing.com - Investing.com Canada
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements - GlobeNewswire
Allarity's Phase 2 Cancer Drug Shows Promise: Patients Exceed 14-Month Treatment | ALLR Stock News - StockTitan
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights - The Manila Times
Allarity Therapeutics Reports $18.5M Cash Position, Extended Runway in Q3 Results | ALLR Stock News - StockTitan
FINAL REMINDER ALLR DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Allarity Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire
DEADLINE ALERT for ALLR, and COIN: The Law Offices of Frank - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - Business Wire
FINAL ALLR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Allarity Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire
ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. - The Bakersfield Californian
ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALLR - GlobeNewswire Inc.
ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR) - Business Wire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - PR Newswire
ALLR Deadline: ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - GuruFocus.com
ALLR FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages - GlobeNewswire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - cnhinews.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - GlobeNewswire
ALLARITY ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm - ForexTV.com
ALLARITY ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
Lawsuit filed for Investors who lost money with shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR) - openPR
Glancy Prongay & Murray LLP Reminds Investors of Looming - GlobeNewswire
DEADLINE ALERT for WBTN, GTLB, ALLR, and COIN: The Law - GlobeNewswire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ALLR 截止日期通知：全球領先的律師事務所 ROSEN 鼓勵 Allarity Therapeutics, Inc. 投資者在證券集體訴訟的重要截止日期 11 月 12 日 之前聘請律師 - GlobeNewswire Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesALLR - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors - GlobeNewswire
ALLR DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, - GlobeNewswire
Allr Deadline Notice: Rosen, A Global And Leading Law Firm, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – ALLR - Wahanariau
Allarity Therapeutics stock hits 52-week low at $1.32 amid steep decline - Investing.com Australia
Allarity Therapeutics stock hits 52-week low at $1.32 amid steep decline By Investing.com - Investing.com South Africa
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Allarity Therapeutics Inc Stock (ALLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):